Daratumumab for hard-to-clear T-cell leukemia traces
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial tests daratumumab (a targeted antibody medicine) in people with T-cell ALL whose leukemia is not fully gone at very low levels. The goal is to eliminate “minimal residual disease” (MRD) that can predict relapse, so treatment may be more effective after intensive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have T-cell acute lymphoblastic leukemia (T-cell ALL) that is in remission after chemotherapy (first or later remission), or almost in remission (CRi).
- Your leukemia trace level (MRD) is still present or has returned at a level of at least 1 in 10,000 (MRD ≥ 10^-4), confirmed by a central test using flow cytometry.
- You’ve had at least two blocks of intensive chemotherapy before starting this study.
- If you had a bone marrow transplant, you cannot have ongoing graft-versus-host disease (GVHD) that needs ongoing immune-suppressing medicines (small-dose prednisone up to 10 mg/day is allowed).
- Your strength and organs must meet lab/health thresholds (including neutrophils ≥ 750, platelets ≥ 75,000; and liver/kidney/bilirubin within set limits).
- If you could become pregnant or father a child, you must use reliable contraception (or not have sex) during the study and for 3 months after the last dose, and you must agree not to donate eggs/sperm during that time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a targeted immune treatment given after strong pre-treatment (myeloablative chemo plus total-body radiation) before or along with an allogeneic stem cell transplant. It may help prevent the cancer from coming back in young people with high-risk T-cell ALL or certain T-cell lymphomas.
This trial tests if adding the drug daratumumab can clear remaining cancer cells in people with T-cell acute lymphoblastic leukemia (T-ALL) who still have a small amount of leukemia after initial chemotherapy. It aims to reduce the risk of the cancer coming back.
This trial tests whether adding the drug daratumumab to usual chemotherapy helps children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). The goal is to see if the combination improves outcomes without increasing side effects.
This trial tests a new combination of a targeted drug (daratumumab) plus chemotherapy, followed by a stem cell transplant, for people with a rare and aggressive blood cancer called primary plasma cell leukemia. The goal is to see if adding daratumumab improves the chances of getting rid of the cancer and staying in remission.
This trial tests a drug called isatuximab for people with a type of leukemia (T-cell acute lymphoblastic leukemia) that has come back after treatment or that did not go away. Isatuximab targets a protein on the leukemia cells, which might help the immune system fight the disease.
This trial tests a drug called daratumumab for people with aplastic anemia that hasn't improved with standard treatments. The goal is to see if it can help your bone marrow make more blood cells and improve your blood counts.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.